These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19120868)

  • 21. Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease.
    Mitsuyama K; Sata M
    Expert Opin Ther Targets; 2008 Mar; 12(3):301-12. PubMed ID: 18269340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An introduction of the role of probiotics in human infections and autoimmune diseases.
    Sales-Campos H; Soares SC; Oliveira CJF
    Crit Rev Microbiol; 2019 Aug; 45(4):413-432. PubMed ID: 31157574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pouchitis, chronic inflammatory bowel diseases, irritable colon. To prevent with a bacteria-cocktail?].
    MMW Fortschr Med; 2003 Nov; 145(46):49. PubMed ID: 14699836
    [No Abstract]   [Full Text] [Related]  

  • 24. Prebiotics and their long-term influence on the microbial populations of the mouse bowel.
    Santos A; San Mauro M; Díaz DM
    Food Microbiol; 2006 Aug; 23(5):498-503. PubMed ID: 16943043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colonic treatments and targets: issues and opportunities.
    McConnell EL; Liu F; Basit AW
    J Drug Target; 2009 Jun; 17(5):335-63. PubMed ID: 19555265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gut microbiota, inflammation and symptomatic diverticular disease. New insights into an old and neglected disorder.
    Quigley EM
    J Gastrointestin Liver Dis; 2010 Jun; 19(2):127-9. PubMed ID: 20593043
    [No Abstract]   [Full Text] [Related]  

  • 27. [Together strong: probiotics to promote health in people and animals].
    Timmerman HM
    Tijdschr Diergeneeskd; 2006 Oct; 131(19):697-700. PubMed ID: 17052077
    [No Abstract]   [Full Text] [Related]  

  • 28. Interactomics in the human intestine: Lactobacilli and Bifidobacteria make a difference.
    Boesten RJ; de Vos WM
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S163-7. PubMed ID: 18685514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gastrointestinal microflora: probiotics.
    Kolida S; Saulnier DM; Gibson GR
    Adv Appl Microbiol; 2006; 59():187-219. PubMed ID: 16829260
    [No Abstract]   [Full Text] [Related]  

  • 30. Metabolic activity of probiotics-oxalate degradation.
    Murphy C; Murphy S; O'Brien F; O'Donoghue M; Boileau T; Sunvold G; Reinhart G; Kiely B; Shanahan F; O'Mahony L
    Vet Microbiol; 2009 Apr; 136(1-2):100-7. PubMed ID: 19028028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro sensitivity of probiotics to human pancreatic juice.
    Del Piano M; Strozzi P; Barba M; Allesina S; Deidda F; Lorenzini P; Morelli L; Carmagnola S; Pagliarulo M; Balzarini M; Ballarè M; Orsello M; Montino F; Sartori M; Garello E; Capurso L
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S170-3. PubMed ID: 18685498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Probiotics in IBD: mucosal and systemic routes of administration may promote similar effects.
    Foligné B; Grangette C; Pot B
    Gut; 2005 May; 54(5):727-8. PubMed ID: 15831924
    [No Abstract]   [Full Text] [Related]  

  • 33. Probiotics and functional gastrointestinal disorders in children.
    Vandenplas Y; Benninga M
    J Pediatr Gastroenterol Nutr; 2009 Apr; 48 Suppl 2():S107-9. PubMed ID: 19300120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intestinal mucus barrier in normal and inflamed colon.
    Corazziari ES
    J Pediatr Gastroenterol Nutr; 2009 Apr; 48 Suppl 2():S54-5. PubMed ID: 19300126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beneficial effect of probiotics in IBD: are peptidogycan and NOD2 the molecular key effectors?
    Macho Fernandez E; Pot B; Grangette C
    Gut Microbes; 2011 Sep; 2(5):280-6. PubMed ID: 22067939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Bacillus subtilis PB6, a natural probiotic on colon mucosal inflammation and plasma cytokines levels in inflammatory bowel disease.
    Selvam R; Maheswari P; Kavitha P; Ravichandran M; Sas B; Ramchand CN
    Indian J Biochem Biophys; 2009 Feb; 46(1):79-85. PubMed ID: 19374258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibiotics and probiotics in inflammatory bowel disease: why, when, and how.
    Prantera C; Scribano ML
    Curr Opin Gastroenterol; 2009 Jul; 25(4):329-33. PubMed ID: 19444096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selecting, testing and understanding probiotic microorganisms.
    Reid G; Kim SO; Köhler GA
    FEMS Immunol Med Microbiol; 2006 Mar; 46(2):149-57. PubMed ID: 16487295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Probiotics in gastrointestinal pathology].
    Cijevschi C; Rezmireş A; Mihai C; Miuţescu E
    Rev Med Chir Soc Med Nat Iasi; 2002; 107(2):264-7. PubMed ID: 12638270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Baseline microbiota activity and initial bifidobacteria counts influence responses to prebiotic dosing in healthy subjects.
    de Preter V; Vanhoutte T; Huys G; Swings J; Rutgeerts P; Verbeke K
    Aliment Pharmacol Ther; 2008 Mar; 27(6):504-13. PubMed ID: 18081736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.